Latest News
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
GlobeNewswire - Tue Nov 5, 8:09AM CST
GlobeNewswire
Tue Nov 5, 8:09AM CST
Kura Oncology to Report Third Quarter 2024ย Financial Results
GlobeNewswire - Thu Oct 31, 6:30AM CDT
GlobeNewswire
Thu Oct 31, 6:30AM CDT
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
GlobeNewswire - Thu Oct 24, 6:30AM CDT
GlobeNewswire
Thu Oct 24, 6:30AM CDT
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
GlobeNewswire - Wed Oct 23, 6:30AM CDT
GlobeNewswire
Wed Oct 23, 6:30AM CDT
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
GlobeNewswire - Mon Jun 17, 8:00AM CDT
GlobeNewswire
Mon Jun 17, 8:00AM CDT
2 Incredible Growth Stocks to Buy Hand Over Fist
Motley Fool - Wed May 8, 7:30AM CDT
Motley Fool
Wed May 8, 7:30AM CDT
These two healthcare growth stocks could have a lot more room to run.
U.S. equities in the spotlight for price trend enthusiasts
The Globe and Mail - Thu Mar 7, 5:12PM CST
The Globe and Mail
Thu Mar 7, 5:12PM CST
We are looking for price trend-focused opportunities in U.S.-listed equities
Kura Oncology (KURA) Offers Speculators a Profit-Scalping Opportunity
Barchart - Tue Jan 16, 12:00PM CST
Barchart
Tue Jan 16, 12:00PM CST
With bullish traders anticipating a quick pop in KURA stock, outside observers need to pay attention, especially because of the underlying short position.
7 Best Cancer Stocks to Invest in Now
MarketBeat - Fri Jul 28, 2023
MarketBeat
Fri Jul 28, 2023
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now.
Stock Index Futures Move Higher as Investors Await Fed Rate Decision, U.S. PPI Data
Barchart - Wed Jun 14, 2023
Barchart
Wed Jun 14, 2023
June S&P 500 futures (ESM23) are up +0.12%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.16% this morning as market participants braced for the Federal Reserveโs interest rate decision while also awaiting crucial U.S. PPI data.
Kura Oncology Reports Second Quarter 2022 Financial Results
Globe Newswire - Wed Aug 3, 2022
Globe Newswire
Wed Aug 3, 2022
โ Recommended Phase 2 dose for ziftomenib identified, pending FDA review โ โ Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in...
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
Globe Newswire - Tue Aug 2, 2022
Globe Newswire
Tue Aug 2, 2022
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
Kura Oncology to Participate in Three Upcoming Investor Conferences
Globe Newswire - Thu May 26, 2022
Globe Newswire
Thu May 26, 2022
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
Kura Oncology Reports First Quarter 2022 Financial Results
Globe Newswire - Wed May 4, 2022
Globe Newswire
Wed May 4, 2022
โ Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter โ โ...
Kura Oncology to Report First Quarter 2022 Financial Results
Globe Newswire - Wed Apr 27, 2022
Globe Newswire
Wed Apr 27, 2022
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer
Globe Newswire - Fri Apr 8, 2022
Globe Newswire
Fri Apr 8, 2022
โ Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination...
Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting
Globe Newswire - Tue Mar 8, 2022
Globe Newswire
Tue Mar 8, 2022
โ Presentations to highlight significant opportunities targeting farnesyl transferase inhibition โ...
Kura Oncology to Participate in Two Upcoming Investor Conferences
Globe Newswire - Mon Feb 28, 2022
Globe Newswire
Mon Feb 28, 2022
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results
Globe Newswire - Thu Feb 24, 2022
Globe Newswire
Thu Feb 24, 2022
โ Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML โ โ Multiple milestones and data readouts from KOMET-001 expected...
Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results
Globe Newswire - Thu Feb 17, 2022
Globe Newswire
Thu Feb 17, 2022
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
Kura Oncology to Participate in SVB Leerink Global Healthcare Conference
Globe Newswire - Thu Feb 10, 2022
Globe Newswire
Thu Feb 10, 2022
SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
Kura Oncology Expands Leadership Team with Key Promotions
Globe Newswire - Tue Feb 1, 2022
Globe Newswire
Tue Feb 1, 2022
โ Expanded leadership team to support and advance the Company's rapid growth โ...
Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 inย Acute Myeloid Leukemia
Globe Newswire - Thu Jan 20, 2022
Globe Newswire
Thu Jan 20, 2022
โ FDA lifts partial clinical hold following agreement on mitigation strategy for differentiation syndrome โ โ KOMET-001 study to resume screening and...
Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
Globe Newswire - Thu Dec 16, 2021
Globe Newswire
Thu Dec 16, 2021
โ Preclinical data suggest HRAS and PI3Kฮฑ are co-dependent oncogenes in HNSCC โ โ Combination has potential to address up to 50% of patients with HNSCC โ ...